Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 3/20 | 0.39 |
| ▸ | TK2 | O00142 | 5/20 | 0.38 |
| ▸ | PYGM | P11217 | 1/20 | 0.34 |
| ▸ | SQOR | Q9Y6N5 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.32 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10590192 | 1.00 | TK1 (0.39) | TK1TK2PYGMSQORCYP1A2 | |
| SCHEMBL10736899 | 1.00 | TK1 (0.39) | TK1TK2PYGMSQORCYP1A2 | |
| SCHEMBL10428773 | 0.90 | LMNA (0.39) | TK2SQOR | |
| SCHEMBL3179329 | 0.90 | LMNA (0.39) | TK2SQOR | |
| SCHEMBL3185225 | 0.90 | LMNA (0.39) | TK2SQOR | |
| SCHEMBL2419477 | 0.90 | LMNA (0.39) | TK2SQOR | |
| SCHEMBL3183300 | 0.90 | LMNA (0.39) | TK2SQOR | |
| SCHEMBL9745084 | 0.90 | SQOR (0.44) | TK1TK2PYGMSQORCYP1A2 | |
| SCHEMBL9747028 | 0.90 | LMNA (0.39) | TK2SQOR | |
| SCHEMBL9744350 | 0.89 | LMNA (0.40) | TK2SQOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6818227-B1 | SINGLE, WEEKLY DOSAGE CANCER THERAPY AGENT; SUCH AS DIPALMITOYL-5-IODO-2'-DEOXYURIDINE AND POLYETHYLENE GLYCOL | ALZA CORPORATION | 2004-11-16 | — | — | US | disclosed |
| EP-1150658-B1 | METHOD FOR CONTROLLING LIPOSOME SIZE | ALZA CORP (US) | 2004-08-04 | — | — | EP | disclosed |
| US-20030194372-A1 | Radioimaging probes and the use thereof | LIU HU (CA) | 2003-10-16 | — | — | US | disclosed |
| EP-1287016-A2 | RADIOIMAGING PROBES AND THE USE THEREOF | Genesis Group Inc. (CA) | 2003-03-05 | — | — | EP | disclosed |
| WO-2001093918-A2 | RADIOIMAGING PROBES AND THE USE THEREOF | GENESIS GROUP INC. (CA) | 2001-12-13 | — | — | WO | disclosed |
| EP-1150658-A2 | METHOD FOR CONTROLLING LIPOSOME SIZE | Alza Corporation (US) | 2001-11-07 | — | — | EP | disclosed |
| WO-2000045791-A2 | METHOD FOR CONTROLLING LIPOSOME SIZE | ALZA CORPORATION (US) | 2000-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030194372-A1 | Radioimaging probes and the use thereof | LDLR, ASGR1, LIPG | TK1 527/4885TK2 2354/4885PYGM 2671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.